Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
JAB-3312 by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval
JAB-3312 is under clinical development by AbbVie and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Lutikizumab by AbbVie for Hidradenitis Suppurativa: Likelihood of Approval
Lutikizumab is under clinical development by AbbVie and currently in Phase III for Hidradenitis Suppurativa. According to GlobalData, Phase III...
Ibrutinib by AbbVie for Primary CNS Lymphoma: Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase II for Primary CNS Lymphoma. According to GlobalData, Phase...
Venetoclax by AbbVie for Myeloproliferative Disorders: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Myeloproliferative Disorders. According to GlobalData, Phase II...
Venetoclax by AbbVie for Solid Tumor: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Venetoclax by AbbVie for Amyloidosis: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Amyloidosis. According to GlobalData, Phase II drugs...
ABBV-706 by AbbVie for Glioblastoma Multiforme (GBM): Likelihood of Approval
ABBV-706 is under clinical development by AbbVie and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
ABBV-706 by AbbVie for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
ABBV-706 is under clinical development by AbbVie and currently in Phase I for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData,...
ABBV-706 by AbbVie for Small-Cell Lung Cancer: Likelihood of Approval
ABBV-706 is under clinical development by AbbVie and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...
ABBV-706 by AbbVie for Solid Tumor: Likelihood of Approval
ABBV-706 is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Telisotuzumab vedotin by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval
Telisotuzumab vedotin is under clinical development by AbbVie and currently in Pre-Registration for Non-Small Cell Lung Cancer. According to GlobalData,...
Livmoniplimab by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval
Livmoniplimab is under clinical development by AbbVie and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...
Venetoclax by AbbVie for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...
Upadacitinib ER by AbbVie for Oligoarticular Idiopathic Juvenile Arthritis: Likelihood of Approval
Upadacitinib ER is under clinical development by AbbVie and currently in Phase I for Oligoarticular Idiopathic Juvenile Arthritis. According to...
Lemzoparlimab by AbbVie for Follicular Lymphoma: Likelihood of Approval
Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...
Lemzoparlimab by AbbVie for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...
Elsubrutinib by AbbVie for Systemic Lupus Erythematosus: Likelihood of Approval
Elsubrutinib is under clinical development by AbbVie and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...
AGN-193408 SR by AbbVie for Ocular Hypertension: Likelihood of Approval
AGN-193408 SR is under clinical development by AbbVie and currently in Phase II for Ocular Hypertension. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of AbbVie's ABBV-668?
ABBV-668 is a small molecule commercialized by AbbVie, with a leading Phase II program in Ulcerative Colitis. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of AbbVie's Telisotuzumab Vedotin?
Telisotuzumab Vedotin is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase III program in Non-Small Cell Lung...